questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 December 2023 to Question 4318 on Prostate Cancer: Drugs, if he will make a comparative assessment of the (a) decision-making criteria for and (b) process to approve the use of abiraterone acetate to treat locally advanced high-risk non-metastatic prostate cancer in (i) NHS England and NHS Wales and (ii) NHS Scotland.
answerText: There are no plans for a comparative assessment to be made. Health is a devolved matter and decisions on access to medicines in Scotland and Wales are a matter for the devolved administrations.NHS England sent a policy proposition to stakeholders on 29 No...
heading: Prostate Cancer: Drugs